Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $145 price target on Alnylam after the company presented new results from the Phase III ENVISION trial and Phase I/II OLE study of givosiran in Acute Hepatic Poprphyria at the International Congress on Porphyrins and Porphyrias Conference. Tenthoff says the updated OLE data showed that monthly givosiran dosing reduced median annualized attack rate to 0.22 over 30 months, and patient reported outcomes also revealed reduced "daily worst pain" for subjects receiving givosiran, lower use of opioids and improved quality of life. Tenthoff tells investors in a research note that he is "confident" in FDA approval by the February 4 PDUFA date.